These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23459719)

  • 1. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches.
    Oberg K; Casanovas O; Castaño JP; Chung D; Delle Fave G; Denèfle P; Harris P; Khan MS; Kulke MH; Scarpa A; Tang LH; Wiedenmann B
    Clin Cancer Res; 2013 Jun; 19(11):2842-9. PubMed ID: 23459719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the mTOR signaling pathway in neuroendocrine tumors.
    Chan J; Kulke M
    Curr Treat Options Oncol; 2014 Sep; 15(3):365-79. PubMed ID: 25092520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical treatment of neuroendocrine tumours.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
    Faivre S; Sablin MP; Dreyer C; Raymond E
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.
    Capdevila J; Meeker A; García-Carbonero R; Pietras K; Astudillo A; Casanovas O; Scarpa A
    Cancer Metastasis Rev; 2014 Mar; 33(1):345-51. PubMed ID: 24375391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies.
    Barbieri F; Albertelli M; Grillo F; Mohamed A; Saveanu A; Barlier A; Ferone D; Florio T
    Drug Discov Today; 2014 Apr; 19(4):458-68. PubMed ID: 24171952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
    Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New horizons for targeted treatment of neuroendocrine tumors.
    Mangano A; Lianos GD; Roukos DH; Mason SE; Kim HY; Dionigi G
    Future Oncol; 2016; 12(8):1059-65. PubMed ID: 26916705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?
    Raymond E; García-Carbonero R; Wiedenmann B; Grande E; Pavel M
    Cancer Metastasis Rev; 2014 Mar; 33(1):367-72. PubMed ID: 24375390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.
    Wiedenmann B; Pavel M; Kos-Kudla B
    Neuroendocrinology; 2011; 94(3):177-90. PubMed ID: 21893937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
    Krug S; Mordhorst JP; Moser F; Theuerkorn K; Ruffert C; Egidi M; Rinke A; Gress TM; Michl P
    PLoS One; 2019; 14(6):e0218953. PubMed ID: 31237925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
    Chan JA; Kulke MH
    Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy for GI and pancreatic NETs].
    Doi T
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):838-42. PubMed ID: 23863723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New strategies for advanced neuroendocrine tumors in the era of targeted therapy.
    Dong M; Phan AT; Yao JC
    Clin Cancer Res; 2012 Apr; 18(7):1830-6. PubMed ID: 22338018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.
    Dasanu CA; Majumder S; Gopal S; Stoica-Mustafa E; Trikudanathan G
    Expert Opin Pharmacother; 2012 Mar; 13(4):461-71. PubMed ID: 22292707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
    Ito T; Lee L; Jensen RT
    Expert Opin Pharmacother; 2016 Nov; 17(16):2191-2205. PubMed ID: 27635672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving landscape of neuroendocrine tumors.
    Bergsland EK
    Semin Oncol; 2013 Feb; 40(1):4-22. PubMed ID: 23391109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
    Oberg K
    Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.